- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Charles Saunders, MD: Biosimilars in Specialty Pharmacy
Charles Saunders, MD, CEO of Integra Connect, discusses the promise of biosimilars in specialty pharmacy.
Transcript:
How are you seeing biosimilars impact the world of specialty pharmacy?
I think that the promise of biosimilars to bring down the cost of drugs is certainly out there based on the experience that we’ve had with generics. I’m not sure that we’re really seeing the impact as great, though, because the prices of the biosimilars are not that much lower than the other drugs—so, maybe 25% to 35% reduction.
I think also, in some cases, I think providers are not—they might be a little bit more reluctant to switch in the case of a therapeutic agent until there’s more clinical evidence of efficacy. And that’s not the case necessarily with supportive therapy, where it’s much easier to make that switch.
So, impact there, promise still there, I think there could be some pricing advantages to the providers that have a “buy and bill” program or they pay a little bit lower price for the acquisition of the drug. Then, if it’s reimbursed at [average sales prices, ASP] plus 6%, they just have a lower cost basis on a drug, so there’s some economic advantages too.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
